Role of a second transplant in the management of poor-prognosis lymphomas: a report from the European Blood and Bone Marrow Registry

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
E VandenbergheA H Goldstone

Abstract

Treatment of selected patients with poor-prognosis lymphomas with high-dose chemotherapy and marrow or peripheral stem-cell rescue improves prognosis. A second course of myeloablative chemotherapy has been given to some patients, but few data are available on the indications, morbidity, and overall survival associated with this approach. This study was undertaken to evaluate morbidity and identify subgroups of patients who may benefit from a second transplant. Thirty-four patients with lymphoma given two cycles of myeloablative chemotherapy and entered onto the European Blood and Bone Marrow Transplant (EBMT) registry between 1982 and 1995 were included in this study: Hodgkin's disease (HD), n = 12; intermediate/high-grade non-Hodgkin's lymphoma (HG-NHL), n = 17; and low-grade non-Hodgkin's lymphoma (LG-NHL), n = 5. The reason for second transplant, status at transplant, conditioning regimen, morbidity, and both progression-free survival (PFS) and overall survival (OS) were assessed. The second procedure was performed for the following reasons: (1) elective double procedure in four patients, (2) relapse after first transplant in 20, (3) partial remission (PR) after first transplant in eight, and (4) refractory disease after fir...Continue Reading

Citations

May 30, 2003·Bone Marrow Transplantation·P MolleeJ Lipton
Apr 18, 2009·Leukemia & Lymphoma·Tanya M Wildes, Nancy L Bartlett
Mar 7, 2007·Expert Review of Anticancer Therapy·Felicity MurphyDavid Cunningham
Feb 22, 2013·Experimental and Clinical Transplantation : Official Journal of the Middle East Society for Organ Transplantation·Hirotaka TakasakiRika Sakai
Jun 22, 2005·Current Treatment Options in Oncology·Koen van BesienHillard M Lazarus
Jun 1, 2002·Bone Marrow Transplantation·T S LinE A Copelan
Sep 28, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Katharine BransonStephen Mackinnon

❮ Previous
Next ❯

Related Concepts

Related Feeds

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

© 2021 Meta ULC. All rights reserved